ELAN Class Action Notice: Robbins LLP Reminds Shareholders of the Lead Plaintiff Deadline in the Class Action Against Elanco Animal Health Incorporated

Core Viewpoint - A class action lawsuit has been filed against Elanco Animal Health Incorporated for failing to disclose issues related to the approval of its drugs, specifically Zenrelia and Credelio Quattro, during the class period from November 7, 2023, to June 26, 2024 [1][2]. Group 1: Allegations and Company Developments - The lawsuit alleges that Elanco did not disclose that Zenrelia was less safe than previously indicated and that the company was unlikely to meet its own timelines for FDA approval and commercial launch of Zenrelia and Credelio Quattro [4]. - Elanco's press release on June 27, 2024, revealed that Zenrelia would likely include a boxed warning on safety, which could slow product adoption by approximately 25% [3]. - The expected timeline for FDA approval was pushed to the third quarter of 2024 for Zenrelia and the fourth quarter of 2024 for Credelio Quattro, leading to a significant drop in Elanco's stock price by $3.69 per share, or 20.53%, closing at $14.28 per share [3]. Group 2: Legal Proceedings and Shareholder Information - Shareholders interested in participating in the class action must submit their application to serve as lead plaintiff by December 6, 2024 [5]. - The law firm Robbins LLP, which is handling the case, operates on a contingency fee basis, meaning shareholders will not incur fees or expenses unless the case is successful [6].